Tenaya Therapeutics Inc (TNYA) - Total Liabilities
Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) has total liabilities worth $22.11 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TNYA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Tenaya Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Tenaya Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tenaya Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kross Ltd
NSE:KROSS
|
India | Rs1.49 Billion |
|
Fu Chun Shin Machinery Manufacture Co Ltd
TWO:6603
|
Taiwan | NT$5.75 Billion |
|
Golden Long Teng Development Co Ltd
TWO:3188
|
Taiwan | NT$7.84 Billion |
|
Medigen Biotechnology
TWO:3176
|
Taiwan | NT$1.45 Billion |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
USA | $959.00 Million |
|
Malaysia Marine and Heavy Engineering Holdings Bhd
KLSE:5186
|
Malaysia | RM1.85 Billion |
|
Thessaloniki Water Supply & Sewerage Co S.A
AT:EYAPS
|
Greece | €55.08 Million |
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
USA | $57.46 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Tenaya Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Tenaya Therapeutics Inc (TNYA) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tenaya Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Tenaya Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $27.09 Million | -12.88% |
| 2023-12-31 | $31.09 Million | -12.59% |
| 2022-12-31 | $35.57 Million | -6.69% |
| 2021-12-31 | $38.12 Million | +337.07% |
| 2020-12-31 | $8.72 Million | -89.33% |
| 2019-12-31 | $81.74 Million | -- |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more